Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel–carboplatin combination therapy in patients with epithelial ovarian cancer?
Sign Up to like & getrecommendations! Published in 2017 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000000538
Abstract: The aims of this study were to investigate a clinical observation that patients with epithelial ovarian cancer treated with first-line platinum–paclitaxel chemotherapy combination (TP) develop macrocytosis and to explore the possible predictive role of macrocytosis… read more here.
Keywords: macrocytosis; patients treated; schedule; dose dense ... See more keywords